Regulatory Path Retatrutide is not yet approved for the treatment of obesity or type 2 diabetes
Semaglutide 2.4 mg achieved a mean change in body weight from baseline to week 104 of -15.2% in the phase 3b STEP 5 trial, and 77.1% of participants achieved weight loss 5% from baseline at week 104
If retatrutide shows cardiovascular benefit similar to or better than semaglutide, it would significantly strengthen the case for approval and potentially expand the labeled indications
Period Changes Can Have Many Causes So, if women are experiencing period changes on GLP-1s, but theyre not caused by the drug, what is causing them
Retatrutide is not a short-term solution the longest-term patients see the best outcomes
We've been using them safely in medicine for decades nicotine replacement, hormone replacement therapy (HRT), some pain medications, motion sickness drugs, certain heart treatments